tiprankstipranks
Trending News
More News >
Integral Diagnostics Ltd. (AU:IDX)
ASX:IDX
Australian Market
Advertisement

Integral Diagnostics Ltd. (IDX) AI Stock Analysis

Compare
28 Followers

Top Page

AU:IDX

Integral Diagnostics Ltd.

(Sydney:IDX)

Rating:53Neutral
Price Target:
AU$2.50
▼(-6.72%Downside)
The overall stock score reflects a mixed financial performance with robust revenue growth and cash management but significant profitability challenges. Technical indicators are neutral, pointing to mild momentum without strong buying or selling signals. The high P/E ratio highlights valuation concerns, suggesting the stock may be overvalued, which impacts the overall attractiveness.

Integral Diagnostics Ltd. (IDX) vs. iShares MSCI Australia ETF (EWA)

Integral Diagnostics Ltd. Business Overview & Revenue Model

Company DescriptionIntegral Diagnostics Ltd. (IDX) is a leading provider of diagnostic imaging services in Australia and New Zealand. The company operates within the healthcare sector, focusing on the delivery of high-quality radiology services, including X-ray, ultrasound, CT, MRI, and nuclear medicine. With a network of clinics and partnerships with hospitals and medical practitioners, IDX is committed to providing accurate and timely diagnostic imaging to aid in the effective diagnosis and treatment of patients.
How the Company Makes MoneyIntegral Diagnostics Ltd. makes money primarily by offering a comprehensive range of diagnostic imaging services. Revenue is generated through the fees charged for imaging services, which are typically paid by patients, private health insurance, or government healthcare programs. The company's key revenue streams include direct payments from patients and reimbursements from health insurance providers and government agencies. Significant partnerships with hospitals and healthcare providers enhance its service offerings and accessibility, contributing to its earnings. Additionally, IDX may leverage technology and innovation to streamline operations and improve service delivery, further bolstering its financial performance.

Integral Diagnostics Ltd. Financial Statement Overview

Summary
Integral Diagnostics Ltd. demonstrates robust revenue growth and efficient cash management. However, significant challenges are evident in profitability, as seen in negative net income and deteriorating EBIT margins. The high leverage and negative return on equity indicate financial risks. While operational cash flow remains strong, the overall financial health is mixed, with strengths in revenue growth and cash management but weaknesses in profitability and leverage.
Income Statement
45
Neutral
The company shows mixed results in its income statement. Gross profit margin is high at 95.12%, indicating effective cost management relative to revenue. However, the net profit margin is negative due to a net loss, which is a significant concern. Revenue growth is strong at 6.72% year-over-year, demonstrating a positive trend in sales. However, EBIT and EBITDA margins have declined sharply, reflecting operational challenges.
Balance Sheet
60
Neutral
The balance sheet presents a stable financial position with an equity ratio of 40.54%, indicating a solid equity base. However, the debt-to-equity ratio is high at 1.19, pointing to significant leverage that could pose risks in challenging economic conditions. Return on Equity has turned negative due to the net loss, highlighting profitability issues.
Cash Flow
50
Neutral
The cash flow statement reveals steady operational cash flows with an operating cash flow to net income ratio of -1.09, indicating strong cash generation relative to net income despite losses. Free cash flow growth is significant at 54.21%, showcasing effective cash management, but free cash flow to net income ratio is negative, underscoring profitability concerns.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue469.70M440.10M358.74M348.81M274.08M
Gross Profit446.78M97.76M83.84M92.19M72.06M
EBITDA12.33M92.74M69.90M88.94M69.50M
Net Income-60.70M25.04M14.60M31.27M23.03M
Balance Sheet
Total Assets744.28M839.01M783.01M654.90M586.91M
Cash, Cash Equivalents and Short-Term Investments42.44M33.85M123.19M62.20M57.97M
Total Debt357.80M365.08M340.99M308.36M277.85M
Total Liabilities442.57M465.96M435.77M400.16M358.58M
Stockholders Equity301.71M373.05M347.24M254.74M228.33M
Cash Flow
Free Cash Flow42.28M27.42M9.33M49.30M28.37M
Operating Cash Flow66.16M71.42M37.10M69.57M54.25M
Investing Cash Flow-27.90M-128.96M-55.69M-56.66M-93.53M
Financing Cash Flow-29.45M-31.85M81.13M-7.83M75.40M

Integral Diagnostics Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.68
Price Trends
50DMA
2.46
Positive
100DMA
2.38
Positive
200DMA
2.66
Positive
Market Momentum
MACD
0.08
Negative
RSI
64.34
Neutral
STOCH
82.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Positive. The current price of 2.68 is above the 20-day moving average (MA) of 2.59, above the 50-day MA of 2.46, and above the 200-day MA of 2.66, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 64.34 is Neutral, neither overbought nor oversold. The STOCH value of 82.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDX.

Integral Diagnostics Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
AU$13.82B24.556.86%3.83%10.15%6.20%
69
Neutral
AU$553.82M18.3218.39%4.43%7.80%99.87%
60
Neutral
HK$16.84B5.17-7.44%2.89%11.55%-28.15%
55
Neutral
AU$300.02M-0.87%6.62%14.24%-109.59%
53
Neutral
AU$1.03B113.991.14%2.16%7.83%
46
Neutral
€559.12M-4.46%-7.82%98.08%
45
Neutral
AU$81.77M-47.52%44.61%16.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IDX
Integral Diagnostics Ltd.
2.68
0.25
10.29%
AU:HLS
Healius Limited
0.80
-0.27
-25.58%
AU:GSS
Genetic Signatures Ltd.
0.36
-0.41
-53.25%
AU:SHL
Sonic Healthcare Limited
27.96
2.49
9.78%
AU:ACL
Australian Clinical Labs Ltd
2.82
0.32
12.80%
AU:MVF
Monash IVF Group Ltd
0.77
-0.51
-39.84%

Integral Diagnostics Ltd. Corporate Events

Integral Diagnostics to Host FY25 Results Conference Call
Jul 23, 2025

Integral Diagnostics Limited announced it will hold a group investor conference call on August 26, 2025, following the release of its FY25 results. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and operations.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Faces Legal Claim Over Earn-Out Dispute
Jul 23, 2025

Integral Diagnostics Ltd. has been served with a legal claim by the Vendors of the Imaging Queensland business, which it acquired in 2019. The Vendors are seeking damages related to an earn-out valuation dispute, which was previously determined by an independent expert to be $2.2 million. Despite efforts by Integral to resolve the issue based on this valuation, the Vendors have initiated legal proceedings. Integral plans to defend itself in this litigation, which could have implications for its financial provisioning and stakeholder relations.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics CEO Announces Retirement, Initiates Leadership Transition
Jun 6, 2025

Integral Diagnostics (IDX) announced the upcoming retirement of its Managing Director and CEO, Dr. Ian Kadish, effective at the end of FY26. Dr. Kadish has significantly contributed to the company’s growth, transforming it into the second largest radiology provider in Australia and a notable presence in New Zealand. The company is conducting an international search for his successor, aiming for a seamless transition to maintain service standards and capitalize on recent synergies from its merger with Capitol Health.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics to Present at 2025 Macquarie Australia Conference
May 7, 2025

Integral Diagnostics announced its participation in the 2025 Macquarie Australia Conference, where it will present its latest developments. This engagement underscores IDX’s commitment to maintaining its leadership position in the medical imaging industry and highlights its ongoing efforts to enhance service quality and patient care.

Challenger Limited Ceases to be Substantial Holder in Integral Diagnostics
May 5, 2025

Challenger Limited has announced that it and its associated entities have ceased to be substantial holders in Integral Diagnostics Limited. This change in holdings may impact Integral Diagnostics’ shareholder composition and influence its market position, as substantial holders often have significant voting power and influence over company decisions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025